title: [Dose dense chemotherapy in the postoperative adjuvant treatment for breast cancer].
abstract: OBJECTIVE
  To investigate the safety and feasibility of dose dense chemotherapy in the postoperative adjuvant treatment for breast cancer.
  
  
  METHODS
  The data of 114 breast cancer patients treated with adjuvant dose dense chemotherapy was retrospectively analyzed.
  
  
  RESULTS
  114 breast cancer patients received postoperative adjuvant dose dense chemotherapy from Jan. 2004 to March 2005. The patients were treated with different regimens according to their recurrence risk: 43 with paclitaxel + epirubicin (PE), 8 with taxotere + epirubicin (TE), 36 with cyclophosphamide + epirubicin + 5-Fu ( CEF) and 27 with epirubicin +5-Fu (EC). Totally, 111 patients except 3 completed the dose dense chemotherapy smoothly. Major toxicities severer than grade III included: neutropenia in 6.3% of the patients, nausea and vomit in 11.7%, peripheral neuropathy in 3.6%.
  
  
  CONCLUSIONS
  Postoperative adjuvant dose dense chemotherapy for breast cancer patient is feasible and safe, but the long-term outcome still needs further observation.
authors.affiliation: Breast Disease Center, Peking Union Medical College Hospital, Beijing 100730, China.
authors.forename: Yi-dong
authors.initials: YD
authors.lastname: Zhou
authors.forename: Qiang
authors.initials: Q
authors.lastname: Sun
authors.forename: Han-yuan
authors.initials: HY
authors.lastname: Huan
authors.forename: Feng
authors.initials: F
authors.lastname: Mao
authors.forename: Jing-hong
authors.initials: JH
authors.lastname: Guan
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D008207:Lymphatic Metastasis; D008408:Mastectomy / Q000379:methods; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009503:Neutropenia / Q000139:chemically induced; D017239:Paclitaxel / Q000008:administration & dosage; D011184:Postoperative Period; D012189:Retrospective Studies; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D015251:Epirubicin; D003520:Cyclophosphamide; D017239:Paclitaxel; D005472:Fluorouracil